PT Tempo Scan Pacific Tbk (TSPC.JK) Stock
PT Tempo Scan Pacific Tbk

Company profile
PT Tempo Scan Pacific Tbk reported revenue of 14.01 trillion IDR for fiscal year 2025, up 2.6% from fiscal year 2024, and net income of 1.41 trillion IDR. That is a net profit margin of 10.0% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 3.41 trillion IDR, up 4.2% from a year before. Its largest business segment, Consumer Products and Cosmetics, brought in 35% of segment revenue in fiscal year 2025; Indonesia was the largest region with 96%. In Q1 2026 it reported net income of 351.81 billion IDR, against net income of 409.25 billion IDR a year earlier. Our analysis of its filings shows revenue growing from 13.12 trillion IDR in fiscal year 2023 to 14.01 trillion IDR in fiscal year 2025, 3.3% a year on average. PT Tempo Scan Pacific Tbk reports about 4,370 full-time employees.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About PT Tempo Scan Pacific Tbk
PT Tempo Scan Pacific Tbk engages in the pharmaceuticals, personal care and cosmetics, and distribution services businesses in Indonesia and internationally. The company operates through Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services segments. It is involved in the pharmaceutical and medical devices trading; manufacture of soaps, herbal products, powder milk, food and beverages, and plastic packaging; and manufacturing and trading of consumer products, cosmetics, and household products. The company sells its products under the Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Vidoran, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, Total Care, and ULTIMA II brands. It also engages in the construction and rental of buildings; Trading, fresh milk processing, livestock, and agriculture; cosmetics retailer and e-commerce; advertising and promotion, research and development, and information technology and communication network systems services; and procurement, distribution, and marketing activities. The company was formerly known as PT Scanchemie. PT Tempo Scan Pacific Tbk was founded in 1970 and is based in Jakarta, Indonesia. The company operates as a subsidiary of PT Bogamulia Nagadi.
Largest shareholders
- PT Bogamulia Nagadi89.71%
- Monega Kapitalanlagegesellschaft mbH0.01%
- PT Indo Premier Securities (Investment Management)0.01%
- Andbank Asset Management Luxembourg SA0.00%
- Niche Asset Management Ltd.0.00%
Share of the company, as of September 25, 2026
Leadership
- I Made Dharma Wijaya — President Director and MD of Sales & Operation - Distribution Division, 55
- Kartika Chandra Sutantio — Corporate Finance & Treasury Director
- . Shania — Group General Counsel Director, Corporate Secretary & Director, 51
- Linda Lukitasari — Research & Development Director and Director, 58
- Nina Muthmainnah — Managing Director of International Business and License Cosmetics
How much revenue does PT Tempo Scan Pacific Tbk make?
PT Tempo Scan Pacific Tbk reported 14.01 trillion IDR in revenue for fiscal year 2025, up 2.6% from 13.65 trillion IDR in fiscal year 2024. In Q1 2026 revenue was 3.41 trillion IDR.
What is PT Tempo Scan Pacific Tbk's largest business segment?
Consumer Products and Cosmetics, with 4.86 trillion IDR or 35% of segment revenue in fiscal year 2025. Next: Pharmaceuticals (34%) and Distribution Services (31%).
Where does PT Tempo Scan Pacific Tbk make most of its revenue?
Indonesia: 96% of revenue by region in fiscal year 2025, followed by International (4%).
What companies are similar to PT Tempo Scan Pacific Tbk?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Kalbe Farma Tbk. (KLBF.JK), PT Darya-Varia Laboratoria Tbk (DVLA.JK), PT Merck Tbk (MERK.JK), PT Pyridam Farma Tbk (PYFA.JK).
How has PT Tempo Scan Pacific Tbk's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 11.23 trillion IDR; FY2022, 12.25 trillion IDR; FY2023, 13.12 trillion IDR; FY2024, 13.65 trillion IDR; FY2025, 14.01 trillion IDR.
Company Information
Data as of .
How to cite: DataPorium, “PT Tempo Scan Pacific Tbk (TSPC.JK)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/TSPC.JK